Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Mallinckrodt
Argus Health
Cipla
UBS
Moodys
Deloitte
Medtronic
Colorcon

Generated: June 24, 2018

DrugPatentWatch Database Preview

VYTORIN Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Vytorin, and when can generic versions of Vytorin launch?

Vytorin is a drug marketed by Msd Intl and is included in one NDA.

The generic ingredient in VYTORIN is ezetimibe; simvastatin. There are twenty-four drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the ezetimibe; simvastatin profile page.
Drug patent expirations by year for VYTORIN
Synonyms for VYTORIN
444313-53-5
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-((3S)-3-(4-fluoro
DTXSID80196177
Ezetimibe and simvastatin
Ezetimibe mixture with Simvastatin
Ezetimibe-simvastatin combination
ezetimibe, simvastatin drug combination
Ezetimibe/simvastatin
INEGY
LS-187957
MK 0653A
PNAMDJVUJCJOIX-IUNFJCKHSA-N
Simvastatin and ezetimibe

US Patents and Regulatory Information for VYTORIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Intl VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-001 Jul 23, 2004 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Msd Intl VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-004 Jul 23, 2004 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Msd Intl VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-002 Jul 23, 2004 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Msd Intl VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-003 Jul 23, 2004 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for VYTORIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Msd Intl VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-001 Jul 23, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Msd Intl VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-004 Jul 23, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Msd Intl VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-002 Jul 23, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Msd Intl VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-002 Jul 23, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VYTORIN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg ➤ Subscribe 2009-07-27

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Moodys
UBS
Express Scripts
Mallinckrodt
Chinese Patent Office
Federal Trade Commission
Medtronic
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.